Rubidium
Cardiogen, Ruby-fill (rubidium) is a small molecule pharmaceutical. Rubidium was first approved as Cardiogen-82 on 1989-12-29.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Cardiogen, Ruby-fill
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rubidium chloride rb-82
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CARDIOGEN-82 | Bracco Diagnostics | N-019414 RX | 1989-12-29 | 1 products |
| RUBY-FILL | Jubilant Therapeutics | N-202153 RX | 2016-09-30 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cardiogen-82 | New Drug Application | 2025-08-13 |
| ruby-fill | New Drug Application | 2020-10-20 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries |
Clinical
Clinical Trials
21 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | — | I25.1 | — | 1 | 1 | — | 8 | 10 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | 1 | 1 | 1 | — | 5 | 8 |
| Coronary disease | D003327 | — | — | — | 1 | 1 | — | 2 | 4 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | 1 | — | — | — | 1 | 2 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 2 | 2 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | — | — | 2 | 2 |
| Radiation exposure | D000069079 | — | — | — | — | — | — | 2 | 2 |
| Angina pectoris | D000787 | EFO_0003913 | I20 | — | — | — | — | 1 | 1 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | — | 1 | 1 |
| Colorectal neoplasms | D015179 | — | — | — | — | — | — | 1 | 1 |
| Salivary gland neoplasms | D012468 | EFO_0003826 | D11 | — | — | — | — | 1 | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | — | — | — | 1 | 1 |
| Head and neck neoplasms | D006258 | — | — | — | — | — | — | 1 | 1 |
Show 18 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rubidium |
| INN | _ |
| Description | Cardiogen, Ruby-fill (rubidium rb-82) is a small molecule pharmaceutical. Rubidium rb-82 was first approved as Cardiogen-82 on 1989-12-29. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | [82Rb] |
Identifiers
| PDB | — |
| CAS-ID | 14391-63-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297424 |
| ChEBI ID | 33322 |
| PubChem CID | 5464265 |
| DrugBank | DB06749 |
| UNII ID | N3SHC5273S (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
Black-box warning for: Cardiogen-82, Ruby-fill
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
155 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use